Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2016-06-08

AUTHORS

A. Balasubramanian, S. W. Wade, R. A. Adler, C. J. F. Lin, M. Maricic, C. D. O’Malley, K. Saag, J. R. Curtis

ABSTRACT

Retrospective claims analysis indicated that high levels of daily and cumulative doses of systemic glucocorticoids were associated with elevated fracture risk in a large cohort of new RA patients under age 65. Heightened risk began to decline within months of discontinuation. Findings were similar among patients age <50 years.IntroductionWe evaluated the impact of systemic glucocorticoid exposure on fracture risk among relatively young patients with new-onset rheumatoid arthritis (RA).MethodsUsing administrative data, we identified 42,127 RA patients diagnosed January 1, 2005–December 31, 2012, age 18–64 years, with benefits coverage for ≥12 months before RA diagnosis. Follow-up extended to clinical fracture, cancer diagnosis, or December 31, 2012. Glucocorticoid users were new to therapy. Fracture incidence rates (IR) were stratified by glucocorticoid exposure expressed as prednisone equivalent doses. Cox’s proportional hazards models estimated fracture risk adjusted for demographics and baseline clinical characteristics to assess dose-response relationships with current (daily) and prior (cumulative) dose, and by time since discontinuation.ResultsMost patients (85 %) had glucocorticoid exposure. Exposed and unexposed patients were demographically similar (74 % female; mean age 49.7 and 48.8 years); 1 % had prior fracture. Fracture IRs (95 % confidence intervals) were 5 to 9 per 1000 person-years at doses <15 mg/day, 16.0 (11.0, 22.6) at doses ≥15 mg/day, and 13.4 (10.7, 16.7) at cumulative doses ≥5400 mg. Adjusted fracture risk was approximately 2-fold higher at highest dose levels compared with 0 mg/day current daily dose and <675 mg cumulative dose, respectively. Fracture risk was 29 % lower at 60–182 days post-discontinuation compared with ongoing use and was similar to unexposed patients by 12 months. Findings were similar among patients age <50 years.ConclusionsAmong younger, new-onset RA patients, fracture risk was significantly elevated at high levels of daily and cumulative dose, and was similar to unexposed patients by 12 months post-discontinuation. More... »

PAGES

3239-3249

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00198-016-3646-z

DOI

http://dx.doi.org/10.1007/s00198-016-3646-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1024146477

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27273113


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Arthritis, Rheumatoid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fractures, Bone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glucocorticoids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Incidence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prednisone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Amgen Inc., Thousand Oaks and San Francisco, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Amgen Inc., Thousand Oaks and San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Balasubramanian", 
        "givenName": "A.", 
        "id": "sg:person.0602043132.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0602043132.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wade Outcomes Research and Consulting, 358 South 700 East, Suite B-432, Salt Lake City, UT, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Wade Outcomes Research and Consulting, 358 South 700 East, Suite B-432, Salt Lake City, UT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wade", 
        "givenName": "S. W.", 
        "id": "sg:person.0617012057.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617012057.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "McGuire Veterans Affairs Medical Center and Virginia Commonwealth University, Richmond, VA, USA", 
          "id": "http://www.grid.ac/institutes/grid.413640.4", 
          "name": [
            "McGuire Veterans Affairs Medical Center and Virginia Commonwealth University, Richmond, VA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Adler", 
        "givenName": "R. A.", 
        "id": "sg:person.01336103271.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336103271.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen Inc., Thousand Oaks and San Francisco, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Amgen Inc., Thousand Oaks and San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lin", 
        "givenName": "C. J. F.", 
        "id": "sg:person.01251164003.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251164003.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Arizona School of Medicine, Tucson, AZ, USA", 
          "id": "http://www.grid.ac/institutes/grid.134563.6", 
          "name": [
            "University of Arizona School of Medicine, Tucson, AZ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maricic", 
        "givenName": "M.", 
        "id": "sg:person.01110701047.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110701047.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen Inc., Thousand Oaks and San Francisco, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Amgen Inc., Thousand Oaks and San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "O\u2019Malley", 
        "givenName": "C. D.", 
        "id": "sg:person.01162363353.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01162363353.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA", 
          "id": "http://www.grid.ac/institutes/grid.265892.2", 
          "name": [
            "Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Saag", 
        "givenName": "K.", 
        "id": "sg:person.016506117177.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016506117177.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA", 
          "id": "http://www.grid.ac/institutes/grid.265892.2", 
          "name": [
            "Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Curtis", 
        "givenName": "J. R.", 
        "id": "sg:person.016600116463.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016600116463.76"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00198-010-1201-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010681993", 
          "https://doi.org/10.1007/s00198-010-1201-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11657-012-0100-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039215702", 
          "https://doi.org/10.1007/s11657-012-0100-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-013-2352-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043901027", 
          "https://doi.org/10.1007/s00198-013-2352-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s001980200108", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040780976", 
          "https://doi.org/10.1007/s001980200108"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-003-1463-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049023520", 
          "https://doi.org/10.1007/s00198-003-1463-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-003-1548-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015568060", 
          "https://doi.org/10.1007/s00198-003-1548-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-06-08", 
    "datePublishedReg": "2016-06-08", 
    "description": "Retrospective claims analysis indicated that high levels of daily and cumulative doses of systemic glucocorticoids were associated with elevated fracture risk in a large cohort of new RA patients under age 65. Heightened risk began to decline within months of discontinuation. Findings were similar among patients age <50\u00a0years.IntroductionWe evaluated the impact of systemic glucocorticoid exposure on fracture risk among relatively young patients with new-onset rheumatoid arthritis (RA).MethodsUsing administrative data, we identified 42,127 RA patients diagnosed January 1, 2005\u2013December 31, 2012, age 18\u201364\u00a0years, with benefits coverage for \u226512\u00a0months before RA diagnosis. Follow-up extended to clinical fracture, cancer diagnosis, or December 31, 2012. Glucocorticoid users were new to therapy. Fracture incidence rates (IR) were stratified by glucocorticoid exposure expressed as prednisone equivalent doses. Cox\u2019s proportional hazards models estimated fracture risk adjusted for demographics and baseline clinical characteristics to assess dose-response relationships with current (daily) and prior (cumulative) dose, and by time since discontinuation.ResultsMost patients (85\u00a0%) had glucocorticoid exposure. Exposed and unexposed patients were demographically similar (74\u00a0% female; mean age 49.7 and 48.8\u00a0years); 1\u00a0% had prior fracture. Fracture IRs (95\u00a0% confidence intervals) were 5 to 9 per 1000 person-years at doses <15\u00a0mg/day, 16.0 (11.0, 22.6) at doses \u226515\u00a0mg/day, and 13.4 (10.7, 16.7) at cumulative doses \u22655400\u00a0mg. Adjusted fracture risk was approximately 2-fold higher at highest dose levels compared with 0\u00a0mg/day current daily dose and <675\u00a0mg cumulative dose, respectively. Fracture risk was 29\u00a0% lower at 60\u2013182\u00a0days post-discontinuation compared with ongoing use and was similar to unexposed patients by 12\u00a0months. Findings were similar among patients age <50\u00a0years.ConclusionsAmong younger, new-onset RA patients, fracture risk was significantly elevated at high levels of daily and cumulative dose, and was similar to unexposed patients by 12\u00a0months post-discontinuation.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00198-016-3646-z", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100834", 
        "issn": [
          "0937-941X", 
          "1433-2965"
        ], 
        "name": "Osteoporosis International", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "11", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "27"
      }
    ], 
    "keywords": [
      "new-onset rheumatoid arthritis", 
      "fracture incidence rates", 
      "fracture risk", 
      "glucocorticoid exposure", 
      "proportional hazards model", 
      "RA patients", 
      "rheumatoid arthritis", 
      "incidence rates", 
      "unexposed patients", 
      "patient age", 
      "cumulative doses", 
      "cumulative dose", 
      "new-onset RA patients", 
      "Cox proportional hazards model", 
      "new RA patients", 
      "systemic glucocorticoid exposure", 
      "current daily dose", 
      "baseline clinical characteristics", 
      "retrospective claims analysis", 
      "elevated fracture risk", 
      "dose-response relationship", 
      "months of discontinuation", 
      "highest dose level", 
      "glucocorticoid users", 
      "ResultsMost patients", 
      "systemic glucocorticoids", 
      "prior fracture", 
      "younger patients", 
      "clinical characteristics", 
      "RA diagnosis", 
      "daily dose", 
      "clinical fractures", 
      "large cohort", 
      "patients", 
      "hazards model", 
      "dose levels", 
      "age 65", 
      "age 18", 
      "doses", 
      "equivalent doses", 
      "dose", 
      "cancer diagnosis", 
      "months", 
      "discontinuation", 
      "high levels", 
      "risk", 
      "arthritis", 
      "administrative data", 
      "claims analysis", 
      "ongoing use", 
      "diagnosis", 
      "exposure", 
      "days", 
      "age", 
      "benefit coverage", 
      "years", 
      "fractures", 
      "glucocorticoids", 
      "findings", 
      "therapy", 
      "cohort", 
      "levels", 
      "IntroductionWe", 
      "demographics", 
      "ConclusionsAmong", 
      "rate", 
      "use", 
      "data", 
      "relationship", 
      "time", 
      "impact", 
      "analysis", 
      "characteristics", 
      "coverage", 
      "model", 
      "users", 
      "MethodsUsing administrative data", 
      "prednisone equivalent doses", 
      "day current daily dose"
    ], 
    "name": "Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis", 
    "pagination": "3239-3249", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1024146477"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00198-016-3646-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27273113"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00198-016-3646-z", 
      "https://app.dimensions.ai/details/publication/pub.1024146477"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:43", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_718.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00198-016-3646-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00198-016-3646-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00198-016-3646-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00198-016-3646-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00198-016-3646-z'


 

This table displays all metadata directly associated to this object as RDF triples.

278 TRIPLES      22 PREDICATES      124 URIs      109 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00198-016-3646-z schema:about N2444d19d041142138a73d556ed3e2ba0
2 N2ca2089cd16f4f35a746adb61ca1959e
3 N3bfac463a6b7459d88c26de25d5e8f99
4 N4d88bd7cef724084897cb70c95b998ef
5 N5b81c2dafecd4a74b4d6d81c21fcac4c
6 N7284242ec2da47efa24af2a6dd77e042
7 N728b8cb2fcc4475a8008db64d2025823
8 N9307ffb4fa0c4ea7b237032d28abd0a3
9 Nae7aefb650c24fecbc161c28727d8dec
10 Nc09c1d499e02498bb19881ee8b4a3b02
11 Nc2a4a46eb0f74353aa2a89d1d8fab180
12 Nd819c6df83e14c8e8c79d28c7a0ac829
13 anzsrc-for:11
14 anzsrc-for:1103
15 anzsrc-for:1117
16 schema:author N5b4151ccfbe94a11a98caf743b72e42b
17 schema:citation sg:pub.10.1007/s00198-003-1463-7
18 sg:pub.10.1007/s00198-003-1548-3
19 sg:pub.10.1007/s00198-010-1201-x
20 sg:pub.10.1007/s00198-013-2352-3
21 sg:pub.10.1007/s001980200108
22 sg:pub.10.1007/s11657-012-0100-5
23 schema:datePublished 2016-06-08
24 schema:datePublishedReg 2016-06-08
25 schema:description Retrospective claims analysis indicated that high levels of daily and cumulative doses of systemic glucocorticoids were associated with elevated fracture risk in a large cohort of new RA patients under age 65. Heightened risk began to decline within months of discontinuation. Findings were similar among patients age <50 years.IntroductionWe evaluated the impact of systemic glucocorticoid exposure on fracture risk among relatively young patients with new-onset rheumatoid arthritis (RA).MethodsUsing administrative data, we identified 42,127 RA patients diagnosed January 1, 2005–December 31, 2012, age 18–64 years, with benefits coverage for ≥12 months before RA diagnosis. Follow-up extended to clinical fracture, cancer diagnosis, or December 31, 2012. Glucocorticoid users were new to therapy. Fracture incidence rates (IR) were stratified by glucocorticoid exposure expressed as prednisone equivalent doses. Cox’s proportional hazards models estimated fracture risk adjusted for demographics and baseline clinical characteristics to assess dose-response relationships with current (daily) and prior (cumulative) dose, and by time since discontinuation.ResultsMost patients (85 %) had glucocorticoid exposure. Exposed and unexposed patients were demographically similar (74 % female; mean age 49.7 and 48.8 years); 1 % had prior fracture. Fracture IRs (95 % confidence intervals) were 5 to 9 per 1000 person-years at doses <15 mg/day, 16.0 (11.0, 22.6) at doses ≥15 mg/day, and 13.4 (10.7, 16.7) at cumulative doses ≥5400 mg. Adjusted fracture risk was approximately 2-fold higher at highest dose levels compared with 0 mg/day current daily dose and <675 mg cumulative dose, respectively. Fracture risk was 29 % lower at 60–182 days post-discontinuation compared with ongoing use and was similar to unexposed patients by 12 months. Findings were similar among patients age <50 years.ConclusionsAmong younger, new-onset RA patients, fracture risk was significantly elevated at high levels of daily and cumulative dose, and was similar to unexposed patients by 12 months post-discontinuation.
26 schema:genre article
27 schema:inLanguage en
28 schema:isAccessibleForFree false
29 schema:isPartOf N1f6c648190d741ec9b1aeb62848d1d50
30 Ndd5c95fe3d944d578b42b5c55b1ffc24
31 sg:journal.1100834
32 schema:keywords ConclusionsAmong
33 Cox proportional hazards model
34 IntroductionWe
35 MethodsUsing administrative data
36 RA diagnosis
37 RA patients
38 ResultsMost patients
39 administrative data
40 age
41 age 18
42 age 65
43 analysis
44 arthritis
45 baseline clinical characteristics
46 benefit coverage
47 cancer diagnosis
48 characteristics
49 claims analysis
50 clinical characteristics
51 clinical fractures
52 cohort
53 coverage
54 cumulative dose
55 cumulative doses
56 current daily dose
57 daily dose
58 data
59 day current daily dose
60 days
61 demographics
62 diagnosis
63 discontinuation
64 dose
65 dose levels
66 dose-response relationship
67 doses
68 elevated fracture risk
69 equivalent doses
70 exposure
71 findings
72 fracture incidence rates
73 fracture risk
74 fractures
75 glucocorticoid exposure
76 glucocorticoid users
77 glucocorticoids
78 hazards model
79 high levels
80 highest dose level
81 impact
82 incidence rates
83 large cohort
84 levels
85 model
86 months
87 months of discontinuation
88 new RA patients
89 new-onset RA patients
90 new-onset rheumatoid arthritis
91 ongoing use
92 patient age
93 patients
94 prednisone equivalent doses
95 prior fracture
96 proportional hazards model
97 rate
98 relationship
99 retrospective claims analysis
100 rheumatoid arthritis
101 risk
102 systemic glucocorticoid exposure
103 systemic glucocorticoids
104 therapy
105 time
106 unexposed patients
107 use
108 users
109 years
110 younger patients
111 schema:name Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis
112 schema:pagination 3239-3249
113 schema:productId N52c0d22579b14a27b973ca36edc74b3a
114 N5b7753451f2645d3aa14c67562e27f26
115 Na8cf97309eef4c048784e56970b79f65
116 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024146477
117 https://doi.org/10.1007/s00198-016-3646-z
118 schema:sdDatePublished 2022-01-01T18:43
119 schema:sdLicense https://scigraph.springernature.com/explorer/license/
120 schema:sdPublisher N7c7b9d158c964dcbbd366c49e3170ee9
121 schema:url https://doi.org/10.1007/s00198-016-3646-z
122 sgo:license sg:explorer/license/
123 sgo:sdDataset articles
124 rdf:type schema:ScholarlyArticle
125 N1f6c648190d741ec9b1aeb62848d1d50 schema:issueNumber 11
126 rdf:type schema:PublicationIssue
127 N2444d19d041142138a73d556ed3e2ba0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Humans
129 rdf:type schema:DefinedTerm
130 N2ca2089cd16f4f35a746adb61ca1959e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Incidence
132 rdf:type schema:DefinedTerm
133 N3af93f06d1e742129d1cc2e85734f32b rdf:first sg:person.01336103271.01
134 rdf:rest Nefeb7b1e95744f2d8403bcb51de88431
135 N3bfac463a6b7459d88c26de25d5e8f99 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Adult
137 rdf:type schema:DefinedTerm
138 N4d88bd7cef724084897cb70c95b998ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Middle Aged
140 rdf:type schema:DefinedTerm
141 N52c0d22579b14a27b973ca36edc74b3a schema:name pubmed_id
142 schema:value 27273113
143 rdf:type schema:PropertyValue
144 N57555f5d0869408d8f87d42cc16c6e49 rdf:first sg:person.01110701047.72
145 rdf:rest N84ef02cd4f4e4a8f8afa96356f794699
146 N5b4151ccfbe94a11a98caf743b72e42b rdf:first sg:person.0602043132.02
147 rdf:rest N784a2094bde64c6f82fd61367348c4df
148 N5b7753451f2645d3aa14c67562e27f26 schema:name dimensions_id
149 schema:value pub.1024146477
150 rdf:type schema:PropertyValue
151 N5b81c2dafecd4a74b4d6d81c21fcac4c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Fractures, Bone
153 rdf:type schema:DefinedTerm
154 N7284242ec2da47efa24af2a6dd77e042 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Retrospective Studies
156 rdf:type schema:DefinedTerm
157 N728b8cb2fcc4475a8008db64d2025823 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Male
159 rdf:type schema:DefinedTerm
160 N784a2094bde64c6f82fd61367348c4df rdf:first sg:person.0617012057.00
161 rdf:rest N3af93f06d1e742129d1cc2e85734f32b
162 N7c7b9d158c964dcbbd366c49e3170ee9 schema:name Springer Nature - SN SciGraph project
163 rdf:type schema:Organization
164 N84ef02cd4f4e4a8f8afa96356f794699 rdf:first sg:person.01162363353.13
165 rdf:rest Nb4c6d15c9b6840f49c60f6bf9f6bd8f1
166 N9307ffb4fa0c4ea7b237032d28abd0a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Risk Factors
168 rdf:type schema:DefinedTerm
169 Na8cf97309eef4c048784e56970b79f65 schema:name doi
170 schema:value 10.1007/s00198-016-3646-z
171 rdf:type schema:PropertyValue
172 Nae7aefb650c24fecbc161c28727d8dec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Prednisone
174 rdf:type schema:DefinedTerm
175 Nb4c6d15c9b6840f49c60f6bf9f6bd8f1 rdf:first sg:person.016506117177.25
176 rdf:rest Nd80f8ee134fc489cbf1d1f6ad7dcdbfb
177 Nc09c1d499e02498bb19881ee8b4a3b02 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Arthritis, Rheumatoid
179 rdf:type schema:DefinedTerm
180 Nc2a4a46eb0f74353aa2a89d1d8fab180 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Female
182 rdf:type schema:DefinedTerm
183 Nd80f8ee134fc489cbf1d1f6ad7dcdbfb rdf:first sg:person.016600116463.76
184 rdf:rest rdf:nil
185 Nd819c6df83e14c8e8c79d28c7a0ac829 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Glucocorticoids
187 rdf:type schema:DefinedTerm
188 Ndd5c95fe3d944d578b42b5c55b1ffc24 schema:volumeNumber 27
189 rdf:type schema:PublicationVolume
190 Nefeb7b1e95744f2d8403bcb51de88431 rdf:first sg:person.01251164003.13
191 rdf:rest N57555f5d0869408d8f87d42cc16c6e49
192 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
193 schema:name Medical and Health Sciences
194 rdf:type schema:DefinedTerm
195 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
196 schema:name Clinical Sciences
197 rdf:type schema:DefinedTerm
198 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
199 schema:name Public Health and Health Services
200 rdf:type schema:DefinedTerm
201 sg:journal.1100834 schema:issn 0937-941X
202 1433-2965
203 schema:name Osteoporosis International
204 schema:publisher Springer Nature
205 rdf:type schema:Periodical
206 sg:person.01110701047.72 schema:affiliation grid-institutes:grid.134563.6
207 schema:familyName Maricic
208 schema:givenName M.
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110701047.72
210 rdf:type schema:Person
211 sg:person.01162363353.13 schema:affiliation grid-institutes:grid.417886.4
212 schema:familyName O’Malley
213 schema:givenName C. D.
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01162363353.13
215 rdf:type schema:Person
216 sg:person.01251164003.13 schema:affiliation grid-institutes:grid.417886.4
217 schema:familyName Lin
218 schema:givenName C. J. F.
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251164003.13
220 rdf:type schema:Person
221 sg:person.01336103271.01 schema:affiliation grid-institutes:grid.413640.4
222 schema:familyName Adler
223 schema:givenName R. A.
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336103271.01
225 rdf:type schema:Person
226 sg:person.016506117177.25 schema:affiliation grid-institutes:grid.265892.2
227 schema:familyName Saag
228 schema:givenName K.
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016506117177.25
230 rdf:type schema:Person
231 sg:person.016600116463.76 schema:affiliation grid-institutes:grid.265892.2
232 schema:familyName Curtis
233 schema:givenName J. R.
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016600116463.76
235 rdf:type schema:Person
236 sg:person.0602043132.02 schema:affiliation grid-institutes:grid.417886.4
237 schema:familyName Balasubramanian
238 schema:givenName A.
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0602043132.02
240 rdf:type schema:Person
241 sg:person.0617012057.00 schema:affiliation grid-institutes:None
242 schema:familyName Wade
243 schema:givenName S. W.
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617012057.00
245 rdf:type schema:Person
246 sg:pub.10.1007/s00198-003-1463-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049023520
247 https://doi.org/10.1007/s00198-003-1463-7
248 rdf:type schema:CreativeWork
249 sg:pub.10.1007/s00198-003-1548-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015568060
250 https://doi.org/10.1007/s00198-003-1548-3
251 rdf:type schema:CreativeWork
252 sg:pub.10.1007/s00198-010-1201-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1010681993
253 https://doi.org/10.1007/s00198-010-1201-x
254 rdf:type schema:CreativeWork
255 sg:pub.10.1007/s00198-013-2352-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043901027
256 https://doi.org/10.1007/s00198-013-2352-3
257 rdf:type schema:CreativeWork
258 sg:pub.10.1007/s001980200108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040780976
259 https://doi.org/10.1007/s001980200108
260 rdf:type schema:CreativeWork
261 sg:pub.10.1007/s11657-012-0100-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039215702
262 https://doi.org/10.1007/s11657-012-0100-5
263 rdf:type schema:CreativeWork
264 grid-institutes:None schema:alternateName Wade Outcomes Research and Consulting, 358 South 700 East, Suite B-432, Salt Lake City, UT, USA
265 schema:name Wade Outcomes Research and Consulting, 358 South 700 East, Suite B-432, Salt Lake City, UT, USA
266 rdf:type schema:Organization
267 grid-institutes:grid.134563.6 schema:alternateName University of Arizona School of Medicine, Tucson, AZ, USA
268 schema:name University of Arizona School of Medicine, Tucson, AZ, USA
269 rdf:type schema:Organization
270 grid-institutes:grid.265892.2 schema:alternateName Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA
271 schema:name Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA
272 rdf:type schema:Organization
273 grid-institutes:grid.413640.4 schema:alternateName McGuire Veterans Affairs Medical Center and Virginia Commonwealth University, Richmond, VA, USA
274 schema:name McGuire Veterans Affairs Medical Center and Virginia Commonwealth University, Richmond, VA, USA
275 rdf:type schema:Organization
276 grid-institutes:grid.417886.4 schema:alternateName Amgen Inc., Thousand Oaks and San Francisco, CA, USA
277 schema:name Amgen Inc., Thousand Oaks and San Francisco, CA, USA
278 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...